Your browser is no longer supported. Please, upgrade your browser.
Settings
ATRC [NASD]
AtriCure, Inc.
Index- P/E- EPS (ttm)-1.13 Insider Own2.00% Shs Outstand44.63M Perf Week10.28%
Market Cap3.47B Forward P/E- EPS next Y-0.91 Insider Trans-35.07% Shs Float43.51M Perf Month17.28%
Income-48.70M PEG- EPS next Q-0.34 Inst Own98.00% Short Float4.52% Perf Quarter31.86%
Sales212.60M P/S16.30 EPS this Y-22.10% Inst Trans0.55% Short Ratio4.48 Perf Half Y120.27%
Book/sh8.77 P/B8.78 EPS next Y27.20% ROA-6.90% Target Price82.71 Perf Year87.56%
Cash/sh5.05 P/C15.26 EPS next 5Y20.00% ROE-11.90% 52W Range34.04 - 79.54 Perf YTD38.37%
Dividend- P/FCF- EPS past 5Y-3.30% ROI-9.30% 52W High-3.16% Beta1.07
Dividend %- Quick Ratio4.50 Sales past 5Y9.70% Gross Margin72.90% 52W Low126.29% ATR3.20
Employees750 Current Ratio5.10 Sales Q/Q11.50% Oper. Margin-21.00% RSI (14)69.87 Volatility5.12% 4.25%
OptionableYes Debt/Eq0.15 EPS Q/Q10.70% Profit Margin-22.90% Rel Volume0.68 Prev Close77.33
ShortableYes LT Debt/Eq0.15 EarningsApr 27 AMC Payout- Avg Volume439.04K Price77.03
Recom1.40 SMA2011.14% SMA5016.41% SMA20049.85% Volume298,317 Change-0.39%
Dec-18-20Reiterated Needham Buy $53 → $63
Nov-06-20Reiterated Needham Buy $63 → $53
Apr-07-20Initiated Oppenheimer Outperform $45
Feb-06-20Initiated BTIG Research Buy $42
Jan-24-20Reiterated Needham Buy $39 → $48
Aug-13-19Downgrade Northland Capital Outperform → Market Perform $30
Apr-12-19Initiated JP Morgan Overweight $37
Oct-04-18Reiterated Needham Buy $36 → $39
Aug-02-18Reiterated Stifel Buy $32 → $34
Aug-02-18Reiterated Needham Buy $32 → $36
Jun-18-18Reiterated Needham Buy $26 → $32
Apr-27-18Reiterated Needham Buy $23 → $26
Jan-16-18Reiterated Needham Buy $25 → $23
Nov-02-17Reiterated Needham Buy $26 → $25
Jul-28-17Reiterated Needham Buy $25 → $26
May-30-17Resumed Piper Jaffray Overweight
Jun-30-16Resumed JMP Securities Mkt Outperform
Oct-28-15Reiterated Needham Buy $30 → $23
Oct-06-15Reiterated Needham Buy $32 → $30
Oct-06-15Reiterated Canaccord Genuity Buy $31 → $28
Apr-30-21 06:57AM  
02:33AM  
Apr-29-21 07:00AM  
Apr-28-21 11:30AM  
Apr-27-21 05:25PM  
04:01PM  
02:45PM  
Apr-08-21 08:00AM  
Apr-06-21 08:00AM  
Mar-02-21 04:01PM  
Feb-24-21 03:01AM  
Feb-23-21 04:25PM  
04:01PM  
02:30PM  
Feb-22-21 10:19AM  
Feb-10-21 08:00AM  
Feb-02-21 08:00AM  
Jan-25-21 11:57PM  
Jan-12-21 08:15AM  
Jan-11-21 07:00AM  
Jan-04-21 08:00AM  
Dec-21-20 08:42AM  
12:12AM  
Dec-19-20 04:45PM  
Dec-14-20 08:00AM  
Dec-04-20 12:00PM  
Nov-19-20 11:44AM  
08:00AM  
Nov-06-20 09:30AM  
Nov-05-20 06:25PM  
04:01PM  
02:30PM  
Oct-29-20 12:35PM  
Oct-26-20 08:00AM  
Oct-13-20 08:00AM  
Oct-06-20 05:41PM  
Sep-28-20 06:39AM  
Sep-01-20 08:00AM  
Aug-06-20 04:00PM  
Aug-03-20 08:55AM  
Jul-30-20 06:39AM  
Jul-29-20 08:00AM  
05:01AM  
Jul-28-20 04:22PM  
04:01PM  
Jul-21-20 12:31PM  
Jul-07-20 08:00AM  
Jun-19-20 12:45PM  
Jun-17-20 04:53AM  
May-11-20 08:10PM  
07:16AM  
May-08-20 08:47AM  
Apr-30-20 11:00AM  
08:30AM  
Apr-29-20 05:25PM  
04:01PM  
Apr-27-20 04:02PM  
Apr-22-20 12:31PM  
Apr-15-20 08:00AM  
Apr-14-20 06:42AM  
Apr-13-20 08:00AM  
Apr-09-20 12:26PM  
08:00AM  
Apr-06-20 04:14PM  
Apr-01-20 03:00PM  
Mar-24-20 05:09PM  
Mar-23-20 02:29PM  
Mar-12-20 09:21AM  
Feb-28-20 02:53PM  
Feb-25-20 10:37PM  
Feb-20-20 05:54AM  
Feb-18-20 04:01PM  
02:30PM  
Feb-03-20 08:00AM  
Jan-31-20 07:33AM  
Jan-28-20 11:15AM  
08:00AM  
Jan-10-20 08:14AM  
Jan-07-20 08:00AM  
Dec-16-19 08:00AM  
Dec-10-19 11:28AM  
Dec-09-19 01:12PM  
Dec-05-19 06:13AM  
Dec-04-19 08:00AM  
Dec-02-19 09:33AM  
Nov-12-19 08:00AM  
Nov-06-19 02:22PM  
Oct-30-19 06:15PM  
04:02PM  
Oct-27-19 02:02PM  
Oct-23-19 10:33AM  
Oct-21-19 08:00AM  
Oct-09-19 06:18PM  
Oct-08-19 11:06AM  
08:00AM  
Sep-02-19 03:18PM  
Aug-28-19 10:50AM  
Aug-27-19 08:00AM  
Aug-26-19 08:00AM  
Aug-14-19 02:26PM  
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEHRWEIN SVENDirectorMay 03Option Exercise19.955,00099,75017,686May 05 07:58 AM
WEHRWEIN SVENDirectorMay 03Sale77.9710,000779,70012,686May 05 07:58 AM
Collar Mark ADirectorApr 01Sale65.283,000195,84072,558Apr 05 08:07 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 12Option Exercise21.0425,000526,000529,795Feb 12 04:30 PM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 12Sale65.0025,0001,625,000504,795Feb 12 04:30 PM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 11Option Exercise21.0425,000526,000529,795Feb 12 04:30 PM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 11Sale64.0025,0001,600,000504,795Feb 12 04:30 PM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 10Option Exercise21.0425,000526,000529,795Feb 12 04:30 PM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 10Sale63.0025,0001,575,000504,795Feb 12 04:30 PM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 09Option Exercise21.0425,000526,000529,795Feb 10 08:52 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 09Sale62.0025,0001,550,000504,795Feb 10 08:52 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 08Option Exercise21.0425,000526,000529,795Feb 10 08:52 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 08Sale61.0025,0001,525,000504,795Feb 10 08:52 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 02Option Exercise21.0425,000526,000529,795Feb 04 09:03 AM
Seith Douglas JChief Operating OfficerFeb 02Sale60.0014,941896,46095,939Feb 04 09:06 AM
CARREL MICHAEL HPresident, CEO, & DirectorFeb 02Sale60.0025,0001,500,000504,795Feb 04 09:03 AM
CARREL MICHAEL HPresident, CEO, & DirectorJan 11Option Exercise21.0425,000526,000529,795Jan 13 04:27 PM
CARREL MICHAEL HPresident, CEO, & DirectorJan 11Sale59.0025,0001,475,000504,795Jan 13 04:27 PM
Noznesky Justin JSVP, Mktg & Business DevelopJan 04Option Exercise18.3015,000274,50066,005Jan 06 07:45 AM
Collar Mark ADirectorJan 04Sale55.363,000166,08075,558Jan 06 07:47 AM
Noznesky Justin JSVP, Mktg & Business DevelopJan 04Sale53.5823,3971,253,71342,608Jan 06 07:45 AM
CARREL MICHAEL HPresident, CEO, & DirectorDec 28Option Exercise21.0424,953525,011529,457Dec 28 08:09 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 28Sale58.0024,9531,447,274504,504Dec 28 08:09 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 23Option Exercise21.0447989504,551Dec 28 08:09 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 23Sale58.00472,726504,504Dec 28 08:09 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 22Option Exercise21.0450,0001,052,000529,594Dec 23 04:23 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 22Sale56.5050,0002,825,000504,504Dec 23 04:23 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 21Option Exercise21.0424,751520,761529,255Dec 23 04:23 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 21Sale55.0024,7511,361,305504,504Dec 23 04:23 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 18Option Exercise21.0450,2491,057,239554,753Dec 21 05:07 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 18Sale53.5150,2492,688,824504,504Dec 21 05:07 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 17Option Exercise10.9575,000821,500529,504Dec 21 05:07 PM
CARREL MICHAEL HPresident, CEO, & DirectorDec 17Sale51.0075,0003,825,000504,504Dec 21 05:07 PM
Privitera SalvatoreChief Technical OfficerDec 17Sale51.3310,654546,87068,262Dec 21 05:03 PM
Seith Douglas JChief Operating OfficerDec 17Sale50.0018,617930,850110,880Dec 21 05:00 PM
Privitera SalvatoreChief Technical OfficerDec 09Sale47.503,846182,68578,916Dec 11 07:52 AM
Drake Scott WilliamDirectorNov 17Buy40.5412,350500,66941,036Nov 19 07:40 AM
Seith Douglas JChief Operating OfficerOct 09Sale40.0929,1611,169,064129,497Oct 13 08:23 AM
Collar Mark ADirectorOct 06Sale40.002,33093,20078,558Oct 08 08:39 AM
Collar Mark ADirectorOct 01Sale40.2067026,93480,888Oct 05 08:45 AM
GROVES REGINA EDirectorSep 14Sale41.836,313264,07321,809Sep 16 04:12 PM
Collar Mark ADirectorJul 01Sale44.604,000178,40081,558Jul 06 08:21 AM
Collar Mark ADirectorMay 12Option Exercise5.1510,00051,50083,106May 14 08:12 AM
CARREL MICHAEL HPresident, CEO, & DirectorMay 12Option Exercise5.9125,000147,750539,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 12Sale47.0025,0001,175,000514,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 11Option Exercise5.9125,000147,750539,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 11Sale46.0025,0001,150,000514,147May 13 04:57 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 08Option Exercise5.9125,000147,750539,147May 08 05:02 PM
CARREL MICHAEL HPresident, CEO, & DirectorMay 08Sale45.0025,0001,125,000514,147May 08 05:02 PM
CDXS Codexis, Inc. daily Stock Chart
CDXS [NASD]
Codexis, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own0.80% Shs Outstand60.49M Perf Week-17.57%
Market Cap1.34B Forward P/E- EPS next Y-0.64 Insider Trans-16.65% Shs Float53.09M Perf Month-20.03%
Income-24.00M PEG- EPS next Q-0.20 Inst Own96.60% Short Float11.80% Perf Quarter-27.26%
Sales69.10M P/S19.36 EPS this Y-91.60% Inst Trans1.95% Short Ratio10.21 Perf Half Y56.98%
Book/sh2.81 P/B7.25 EPS next Y-4.90% ROA-14.80% Target Price27.50 Perf Year72.69%
Cash/sh2.28 P/C8.91 EPS next 5Y15.00% ROE-21.10% 52W Range10.28 - 29.56 Perf YTD-6.73%
Dividend- P/FCF- EPS past 5Y-16.00% ROI-14.30% 52W High-31.12% Beta1.27
Dividend %- Quick Ratio7.30 Sales past 5Y10.60% Gross Margin80.10% 52W Low98.06% ATR1.34
Employees181 Current Ratio7.40 Sales Q/Q12.30% Oper. Margin-34.60% RSI (14)35.64 Volatility6.19% 5.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-498.40% Profit Margin-34.80% Rel Volume0.61 Prev Close20.73
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout- Avg Volume614.05K Price20.36
Recom1.60 SMA20-14.25% SMA50-9.42% SMA20010.56% Volume378,740 Change-1.78%
Apr-12-21Initiated Piper Sandler Overweight $32
Mar-01-21Initiated Stifel Buy $30
Feb-26-21Reiterated H.C. Wainwright Buy $21 → $26
Mar-10-20Initiated The Benchmark Company Buy
Jan-17-19Upgrade First Analysis Sec Neutral → Outperform $12 → $19
May-16-18Initiated Stephens Overweight $16
Oct-13-17Reiterated H.C. Wainwright Buy $8 → $8.50
May-31-17Initiated Jefferies Buy $8
Jan-26-17Downgrade First Analysis Sec Overweight → Equal-Weight $5.50
Jan-04-17Upgrade Ladenburg Thalmann Neutral → Buy
Jan-06-16Initiated H.C. Wainwright Buy $6
Apr-22-21 04:05PM  
Apr-05-21 03:10PM  
Mar-30-21 02:51AM  
Mar-01-21 10:14AM  
Feb-25-21 04:55PM  
04:05PM  
02:30PM  
Feb-18-21 04:05PM  
Feb-16-21 05:59AM  
Feb-13-21 02:19AM  
Feb-11-21 04:05PM  
Feb-09-21 04:05PM  
Feb-03-21 04:05PM  
Jan-13-21 07:00AM  
Jan-08-21 12:55AM  
Jan-05-21 07:00AM  
Dec-31-20 07:31PM  
Dec-30-20 02:50PM  
Dec-14-20 11:39AM  
Dec-08-20 12:44AM  
Dec-02-20 11:11PM  
04:25PM  
Nov-24-20 05:02PM  
Nov-09-20 07:00AM  
Nov-07-20 08:38AM  
Nov-05-20 08:30PM  
04:05PM  
02:45PM  
Oct-29-20 07:00AM  
Sep-08-20 07:00AM  
Aug-11-20 08:33AM  
Aug-06-20 04:05PM  
07:00AM  
Jul-30-20 07:00AM  
Jul-28-20 12:33PM  
Jun-23-20 07:00AM  
Jun-22-20 03:06PM  
Jun-16-20 04:05PM  
Jun-14-20 03:50PM  
Jun-01-20 04:05PM  
May-27-20 07:00AM  
May-22-20 07:31PM  
May-11-20 07:00AM  
06:51AM  
May-09-20 01:30AM  
May-07-20 04:05PM  
May-06-20 04:05PM  
May-05-20 07:00AM  
Apr-30-20 07:00AM  
Apr-27-20 12:31PM  
Apr-07-20 08:37AM  
Mar-23-20 07:00AM  
Mar-13-20 01:57PM  
Mar-02-20 10:15AM  
Mar-01-20 07:19AM  
Feb-27-20 06:55PM  
04:05PM  
Feb-25-20 07:00AM  
Feb-20-20 07:00AM  
Jan-31-20 07:52AM  
Jan-13-20 04:05PM  
Jan-10-20 07:00AM  
Jan-01-20 09:06AM  
Dec-24-19 07:24AM  
Dec-23-19 07:00AM  
Dec-16-19 06:10AM  
Dec-05-19 04:05PM  
Dec-02-19 12:32PM  
Nov-16-19 09:39PM  
Nov-06-19 09:00AM  
Nov-05-19 07:55PM  
04:05PM  
07:00AM  
Oct-29-19 07:00AM  
Oct-27-19 08:13PM  
Oct-26-19 09:13AM  
Oct-15-19 04:05PM  
Sep-26-19 08:00AM  
07:00AM  
Sep-20-19 06:57AM  
Aug-29-19 07:11AM  
Aug-22-19 11:15PM  
Aug-09-19 01:32PM  
Aug-07-19 03:49PM  
08:25AM  
Aug-06-19 07:35PM  
04:06PM  
Jul-30-19 07:00AM  
Jun-27-19 03:01PM  
Jun-20-19 07:00AM  
Jun-10-19 12:06PM  
May-30-19 07:00AM  
May-16-19 09:34AM  
May-15-19 09:00AM  
May-14-19 04:05PM  
May-10-19 01:51AM  
May-09-19 10:07AM  
May-07-19 10:57AM  
03:23AM  
May-06-19 07:25PM  
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KELLEY BERNARD JDirectorApr 21Sale22.642,50056,608206,136Apr 22 04:12 PM
Yang Patrick YDirectorApr 05Sale24.2710,000242,73283,716Apr 07 04:48 PM
WOLF DENNIS PDirectorMar 25Sale20.4410,000204,35141,129Mar 29 04:07 PM
KELLEY BERNARD JDirectorMar 08Option Exercise10.5120,000210,200228,636Mar 09 04:20 PM
KELLEY BERNARD JDirectorMar 08Sale18.7220,000374,350208,636Mar 09 04:20 PM
Dorgan Byron LDirectorJan 21Option Exercise10.6325,000265,750187,790Jan 21 07:29 PM
KELLEY BERNARD JDirectorJan 21Sale24.982,50062,439208,636Jan 21 07:30 PM
Dorgan Byron LDirectorJan 21Sale25.1725,000629,195162,790Jan 21 07:29 PM
Dorgan Byron LDirectorJan 20Option Exercise10.6325,000265,750187,790Jan 21 07:29 PM
Dorgan Byron LDirectorJan 20Sale26.7525,000668,658162,790Jan 21 07:29 PM
WOLF DENNIS PDirectorDec 21Sale19.9910,000199,87451,129Dec 22 04:08 PM
KELLEY BERNARD JDirectorOct 21Sale14.002,50035,007211,136Oct 23 04:04 PM
Dorgan Byron LDirectorOct 09Option Exercise10.6325,000265,750187,790Oct 13 04:04 PM
Dorgan Byron LDirectorOct 09Sale13.5425,000338,528162,790Oct 13 04:04 PM
Dorgan Byron LDirectorOct 08Option Exercise10.6325,000265,750187,790Oct 13 04:04 PM
Dorgan Byron LDirectorOct 08Sale13.4925,000337,315162,790Oct 13 04:04 PM
WOLF DENNIS PDirectorSep 24Sale11.6810,000116,84561,129Sep 28 04:03 PM
KELLEY BERNARD JDirectorJul 21Sale12.792,50031,965213,636Jul 23 04:16 PM
WOLF DENNIS PDirectorJun 25Sale10.9710,000109,69471,129Jun 26 04:18 PM
BARUCH THOMAS RDirectorJun 12Sale10.614,94752,46433,093Jun 16 04:03 PM
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.07 Insider Own4.70% Shs Outstand78.91M Perf Week3.88%
Market Cap5.85B Forward P/E- EPS next Y-4.50 Insider Trans-0.45% Shs Float75.12M Perf Month-1.57%
Income-554.10M PEG- EPS next Q-1.78 Inst Own89.80% Short Float9.67% Perf Quarter-21.30%
Sales540.10M P/S10.83 EPS this Y26.80% Inst Trans0.16% Short Ratio6.57 Perf Half Y-47.00%
Book/sh9.65 P/B7.54 EPS next Y34.60% ROA-19.10% Target Price- Perf Year-39.07%
Cash/sh24.11 P/C3.02 EPS next 5Y- ROE-57.70% 52W Range68.04 - 181.83 Perf YTD-57.32%
Dividend- P/FCF231.25 EPS past 5Y-6.40% ROI-32.20% 52W High-59.98% Beta1.45
Dividend %- Quick Ratio5.40 Sales past 5Y236.40% Gross Margin88.30% 52W Low6.95% ATR2.92
Employees866 Current Ratio6.00 Sales Q/Q45.00% Oper. Margin- RSI (14)47.33 Volatility4.76% 3.94%
OptionableYes Debt/Eq1.30 EPS Q/Q24.10% Profit Margin- Rel Volume0.89 Prev Close74.02
ShortableYes LT Debt/Eq1.30 EarningsMay 05 AMC Payout- Avg Volume1.11M Price72.77
Recom2.20 SMA201.46% SMA50-6.34% SMA200-40.59% Volume981,643 Change-1.69%
Apr-26-21Resumed Credit Suisse Neutral $72
Jan-12-21Downgrade Citigroup Buy → Neutral $215 → $108
Jan-11-21Downgrade UBS Buy → Neutral
Jan-08-21Downgrade Raymond James Outperform → Mkt Perform
Jan-08-21Downgrade Morgan Stanley Overweight → Equal-Weight $95
Jan-08-21Downgrade JP Morgan Overweight → Underweight $96
Nov-11-20Initiated Berenberg Hold
Oct-28-20Initiated UBS Buy $212
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
May-06-21 03:01AM  
May-05-21 07:15PM  
04:05PM  
02:45PM  
May-04-21 04:30PM  
May-03-21 01:22PM  
08:50AM  
08:02AM  
Apr-30-21 06:45PM  
04:05PM  
06:06AM  
Apr-28-21 12:34PM  
08:30AM  
Apr-26-21 04:05PM  
Apr-07-21 04:53PM  
Apr-01-21 10:39AM  
Mar-25-21 07:47AM  
Mar-23-21 08:30AM  
Mar-19-21 04:24PM  
Mar-18-21 04:31PM  
Mar-15-21 08:30AM  
Mar-02-21 10:02AM  
08:57AM  
02:01AM  
Mar-01-21 05:55PM  
04:28PM  
04:05PM  
02:30PM  
Feb-26-21 07:12PM  
10:16AM  
Feb-25-21 03:48PM  
02:10PM  
Feb-24-21 04:30PM  
Feb-22-21 08:30AM  
05:48AM  
Feb-16-21 09:11AM  
Feb-15-21 09:39PM  
Feb-13-21 03:30PM  
Feb-11-21 12:37PM  
Feb-08-21 07:10PM  
11:11AM  
Feb-06-21 11:18PM  
Feb-04-21 07:01PM  
04:30PM  
Feb-03-21 11:15AM  
Feb-01-21 05:16PM  
Jan-29-21 08:30PM  
Jan-22-21 07:00AM  
Jan-21-21 10:35AM  
Jan-15-21 01:20PM  
Jan-14-21 12:28PM  
10:26AM  
Jan-13-21 01:00PM  
08:30AM  
Jan-12-21 01:30PM  
10:17AM  
08:57AM  
06:00AM  
Jan-11-21 08:01PM  
03:11PM  
02:45PM  
12:00PM  
08:11AM  
Jan-10-21 01:00PM  
07:56AM  
Jan-09-21 07:15PM  
01:15PM  
Jan-08-21 07:23PM  
06:48PM  
05:16PM  
04:30PM  
01:35PM  
01:25PM  
11:57AM  
11:44AM  
11:38AM  
10:15AM  
09:39AM  
09:36AM  
09:08AM  
08:30AM  
Jan-07-21 05:13PM  
05:11PM  
04:05PM  
Jan-06-21 04:15PM  
Jan-05-21 06:00AM  
Jan-04-21 10:32AM  
Dec-31-20 06:30PM  
Dec-24-20 04:41AM  
Dec-22-20 12:56PM  
Dec-20-20 03:14PM  
Dec-18-20 02:00PM  
Dec-14-20 08:30AM  
Dec-09-20 10:42AM  
Dec-08-20 10:07AM  
Dec-07-20 01:57PM  
08:55AM  
Dec-05-20 11:32AM  
Dec-04-20 04:05PM  
Nov-30-20 06:05PM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorMar 10Option Exercise42.305,000211,500135,517Mar 10 08:04 PM
BEHRENS M KATHLEENDirectorMar 10Sale85.765,000428,800130,517Mar 10 08:04 PM
Wigzell Hans Lennart RudolfDirectorMar 08Option Exercise34.9210,000349,20026,518Mar 10 08:03 PM
Wigzell Hans Lennart RudolfDirectorMar 08Sale83.5110,000835,10016,518Mar 10 08:03 PM
Bratica JosephPrincipal Financial OfficerDec 11Option Exercise71.451,11579,6679,255Dec 14 08:00 PM
Bratica JosephPrincipal Financial OfficerDec 11Sale165.001,115183,9758,140Dec 14 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096705,710Dec 10 08:24 PM
Bratica JosephPrincipal Financial OfficerDec 08Option Exercise29.601,12533,3009,265Dec 10 08:23 PM
Bratica JosephPrincipal Financial OfficerDec 08Sale160.001,125180,0008,140Dec 10 08:23 PM
Wigzell Hans Lennart RudolfDirectorAug 10Option Exercise34.9210,000349,20023,792Aug 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 10Sale159.0010,0001,590,04413,792Aug 11 08:00 PM
Barry RichardDirectorAug 07Sale158.5030,0004,754,9723,129,140Aug 07 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Option Exercise29.601,12533,3008,957Aug 05 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Sale155.001,125174,3757,832Aug 05 08:00 PM
Mahatme SandeshEVP, CFO & CBOJul 08Option Exercise19.693,80674,94120,260Jul 09 08:00 PM
Howton David TEVP, General CounselJun 22Option Exercise25.76105,1222,708,440136,993Jun 22 09:17 PM
Howton David TEVP, General CounselJun 22Sale170.88105,12217,962,83131,871Jun 22 09:17 PM
Wigzell Hans Lennart RudolfDirectorMay 20Option Exercise10.085,00050,40018,792May 22 08:00 PM
Wigzell Hans Lennart RudolfDirectorMay 20Sale150.645,000753,21013,792May 22 08:00 PM
Barry RichardDirectorMay 15Sale141.2630,0004,237,9463,159,140May 15 09:02 PM